The anti-leukemia response was shown in two separate phases: a CD8+ or CD4-CD8-Helios^hi γδ CAR-T cell-dominated initial phase, which was followed by a majority proliferative CD4+ CAR-T cell population in subsequent years (68). The gene discussed is CD8A; the disease is leukemia.